Drug Profile
Ruboxistaurin - Chromaderm/Recursion Pharmaceuticals
Alternative Names: Arxxant; DBI-102; LY-333531; REC 3599; SM 030Latest Information Update: 03 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer DermBiont; Eli Lilly and Company; Recursion Pharmaceuticals; Takeda
- Class Eye disorder therapies; Heart failure therapies; Indoles; Maleimides; Skin disorder therapies
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Protein kinase C beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperpigmentation; Melanosis; Skin disorders
- Discontinued Diabetic macular oedema; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; GM2 gangliosidoses; Heart failure
Most Recent Events
- 31 Dec 2022 Discontinued - Phase-I for GM2 gangliosidoses in USA (PO)
- 18 Aug 2022 Phase-II clinical trials in Hyperpigmentation in El Salvador (Topical) (NCT05511948)
- 07 Mar 2022 Phase-I clinical trials in GM2 gangliosidoses in USA (PO) before March 2022 (Recursion Pharmaceuticals' pipeline, March 2022)